Immunotherapy plus chemo shows promise against tough throat cancer
NCT ID NCT05340270
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding a PD-1 inhibitor (a type of immunotherapy) to standard chemotherapy before radiation can improve outcomes for people with advanced nasopharyngeal carcinoma. About 150 participants will receive either the combination or chemotherapy alone, followed by standard chemoradiation. The main goal is to see if the combination delays cancer progression or death.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PD-1 inhibitor (a type of immunotherapy) plus gemcitabine and cisplatin chemotherapy
What this could lead to
If successful, this combination could become a new standard approach to shrink advanced nasopharyngeal tumors before radiation, potentially improving long-term survival.
What could go wrong
This is a mid-stage trial with only 150 participants, so results may not apply to all patients. Adding immunotherapy also raises the risk of immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, 530021, China